How we review peer review

In case you have never attended an open house workshop at the NIH's Center for Scientific Review, in which people who participate in NIH peer review gather to discuss how the process is going and could improve, here's how it typically goes: Tuesday morning (December 18), about 80 stakeholders such as study section leaders in the Biomolecular group (about one-sixth of the entire CSR) gathered in a large auditorium of the Natcher Building on the NIH campus to consider two questions. 1. W

Written byAlison McCook
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
In case you have never attended an open house workshop at the NIH's Center for Scientific Review, in which people who participate in NIH peer review gather to discuss how the process is going and could improve, here's how it typically goes: Tuesday morning (December 18), about 80 stakeholders such as study section leaders in the Biomolecular group (about one-sixth of the entire CSR) gathered in a large auditorium of the Natcher Building on the NIH campus to consider two questions. 1. What will be the most important questions and/or enabling technologies you see forthcoming within the science of your discipline in the next 10 years? 2. Is the science of your discipline, in its present state, appropriately evaluated within the current study section alignment? Suggestions? (Note: Concurrent to the CSR review, the NIH is conducting an agency-wide review of peer review. You can linkurl:weigh in;http://www.the-scientist.com/news/display/54009/ on some of the changes the agency is considering.) The attendees divided into three groups: Biophysics and Cell Biology (BCB); Biochemistry, Molecular Genetics, Genetics, and Evolution (BMGE); and Computations, Modeling, Large Data Sets, Theory, Genomics, and Proteomics (CMTP). Each group had only one hour to debate each question - with a handful of participants doing most of the talking, as with most group discussions - then feverishly distill the discussion into three essential points, tweaking the wording. Everyone filed back into the auditorium, where study section chair co-facilitators had about five minutes each to present the three points their group designed, followed by approximately 15 minutes for the audience to ask questions or react. Amazingly, the groups often appeared to come to some consensus. The word of the day was "integration" - of tools, multidisciplinary approaches, datasets, experimentalists with computational modeling, knowledge about single molecules/cells/organs, etc. There was much talk about the importance of training people to use bioinformatics tools to evaluate data that have already been accumulated, rather than simply adding more data to the pile. There were definitely points with no consensus, however - are NIH peer reviewers mentoring applicants, meaning providing guidance in how to improve the application, or simply delivering essentially a yay/nay vote? Should they do more mentoring, or less? During the BMGE discussion of question 2, an attendee asked: What happens if peer reviewers recommend a particular experiment, and the applicant goes to the trouble of doing that experiment, and the grant still isn't approved? Reviewers can't mentor applicants "in good conscience if they can't guarantee the application will get funded," he argued. Around lunchtime, CSR Director Toni Scarpa reviewed the changes the agency was already implementing, partly a result of the previous open houses held throughout the year: Shortening the review cycle, reducing the number of initial review groups (IRGs), conducting more reviews electronically. Last year, the CSR received 80,000 grant applications, reviewed 52,000, recruited 18,000 reviewers, and conducted 1,800 review meetings.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies